The global Celiac Diseases Drugs Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Therapy (First line treatment, Second-line treatment), By Route of Administration (Oral, Parenteral).
The Celiac Diseases Drugs Market focuses on pharmaceutical interventions and therapies aimed at managing and treating celiac disease, an autoimmune disorder triggered by gluten consumption. Therapies in this market may include gluten-free diet adherence, enzyme supplements, immunosuppressive medications, and investigational drugs targeting celiac disease mechanisms. In 2024, this market highlights research and development efforts, diagnostic advancements, patient education initiatives, and therapeutic innovations for better disease management and quality of life for individuals with celiac disease.
The global Celiac Diseases Drugs Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Celiac Diseases Drugs Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Celiac Diseases Drugs Industry include- 9 Meters Biopharma Inc, Almirall SA, Amgen Inc, AMYRA Biotech AG, Artielle Immunotherapeutics Inc, Avaxia Biologics Inc, BioLineRx Ltd, Bristol Myers Squibb Co., Calypso Biotech BV, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, ImmunogenX Inc, Johnson and Johnson, Precigen Inc, Sanofi, Takeda Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, Vactech Oy, Zedira GmbH.
A prominent trend in the Celiac Diseases Drugs market is the rising diagnosis rates and awareness of celiac disease among healthcare professionals and the general population. With improved understanding of the disease's pathophysiology and advancements in diagnostic techniques, more cases of celiac disease are being accurately diagnosed. Additionally, growing awareness campaigns, patient education initiatives, and advocacy efforts have contributed to increased recognition of celiac disease symptoms and the importance of early diagnosis and adherence to a gluten-free diet. This trend is driving greater demand for celiac disease drugs as more individuals seek effective treatment options to manage their condition and improve their quality of life.
The primary driver for the Celiac Diseases Drugs market is the escalating prevalence of celiac disease worldwide. Celiac disease is a chronic autoimmune disorder characterized by an abnormal immune response to gluten, a protein found in wheat, barley, and rye. The prevalence of celiac disease is increasing globally, with a growing number of individuals being diagnosed across different age groups and ethnicities. Factors such as changes in dietary habits, genetic predisposition, and improved disease recognition contribute to the rising prevalence of celiac disease. As the incidence of celiac disease continues to climb, there is a growing need for effective pharmacological interventions to manage symptoms, treat complications, and prevent long-term health consequences, thus driving the demand for celiac disease drugs.
An opportunity for market growth in the Celiac Diseases Drugs segment lies in the development of novel therapies and biologics specifically targeting celiac disease pathophysiology. While a strict gluten-free diet is the cornerstone of celiac disease management, many patients continue to experience symptoms or face challenges in adhering to dietary restrictions. There is a need for alternative treatment options, including pharmacological therapies that can alleviate symptoms, modulate immune responses, and promote mucosal healing in the small intestine. Additionally, biologic agents targeting key inflammatory pathways involved in celiac disease pathogenesis hold promise as potential therapeutic options. Investing in research and development initiatives focused on discovering and advancing novel drug candidates for celiac disease represents an opportunity to address unmet medical needs, improve patient outcomes, and expand the market for celiac disease drugs.
Among the provided options, the second-line treatment for celiac disease emerges as the fastest-growing segment. Second-line treatments typically refer to therapies used when initial treatments, such as a gluten-free diet (considered the first-line treatment for celiac disease), are ineffective or insufficient in managing the condition. These second-line treatments may include medications or procedures aimed at alleviating symptoms, reducing inflammation, or addressing complications associated with celiac disease. With advancements in medical research and the growing understanding of celiac disease's complexities, there has been an increasing focus on developing and refining second-line treatment options to better meet the needs of patients who do not respond adequately to dietary interventions alone. As a result, the second-line treatment segment is projected to experience notable growth in the market for celiac disease drugs.
By Therapy
First line treatment
Second-line treatment
By Route of Administration
Oral
Parenteral
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
9 Meters Biopharma Inc
Almirall SA
Amgen Inc
AMYRA Biotech AG
Artielle Immunotherapeutics Inc
Avaxia Biologics Inc
BioLineRx Ltd
Bristol Myers Squibb Co.
Calypso Biotech BV
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
ImmunogenX Inc
Johnson and Johnson
Precigen Inc
Sanofi
Takeda Pharmaceutical Co. Ltd
Teva Pharmaceutical Industries Ltd
Vactech Oy
Zedira GmbH
* List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Celiac Diseases Drugs Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Celiac Diseases Drugs Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Celiac Diseases Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Celiac Diseases Drugs Market Size Outlook, $ Million, 2021 to 2030
3.2 Celiac Diseases Drugs Market Outlook by Type, $ Million, 2021 to 2030
3.3 Celiac Diseases Drugs Market Outlook by Product, $ Million, 2021 to 2030
3.4 Celiac Diseases Drugs Market Outlook by Application, $ Million, 2021 to 2030
3.5 Celiac Diseases Drugs Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Celiac Diseases Drugs Industry
4.2 Key Market Trends in Celiac Diseases Drugs Industry
4.3 Potential Opportunities in Celiac Diseases Drugs Industry
4.4 Key Challenges in Celiac Diseases Drugs Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Celiac Diseases Drugs Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Celiac Diseases Drugs Market Outlook by Segments
7.1 Celiac Diseases Drugs Market Outlook by Segments, $ Million, 2021- 2030
By Therapy
First line treatment
Second-line treatment
By Route of Administration
Oral
Parenteral
8 North America Celiac Diseases Drugs Market Analysis and Outlook To 2030
8.1 Introduction to North America Celiac Diseases Drugs Markets in 2024
8.2 North America Celiac Diseases Drugs Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Celiac Diseases Drugs Market size Outlook by Segments, 2021-2030
By Therapy
First line treatment
Second-line treatment
By Route of Administration
Oral
Parenteral
9 Europe Celiac Diseases Drugs Market Analysis and Outlook To 2030
9.1 Introduction to Europe Celiac Diseases Drugs Markets in 2024
9.2 Europe Celiac Diseases Drugs Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Celiac Diseases Drugs Market Size Outlook by Segments, 2021-2030
By Therapy
First line treatment
Second-line treatment
By Route of Administration
Oral
Parenteral
10 Asia Pacific Celiac Diseases Drugs Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Celiac Diseases Drugs Markets in 2024
10.2 Asia Pacific Celiac Diseases Drugs Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Celiac Diseases Drugs Market size Outlook by Segments, 2021-2030
By Therapy
First line treatment
Second-line treatment
By Route of Administration
Oral
Parenteral
11 South America Celiac Diseases Drugs Market Analysis and Outlook To 2030
11.1 Introduction to South America Celiac Diseases Drugs Markets in 2024
11.2 South America Celiac Diseases Drugs Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Celiac Diseases Drugs Market size Outlook by Segments, 2021-2030
By Therapy
First line treatment
Second-line treatment
By Route of Administration
Oral
Parenteral
12 Middle East and Africa Celiac Diseases Drugs Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Celiac Diseases Drugs Markets in 2024
12.2 Middle East and Africa Celiac Diseases Drugs Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Celiac Diseases Drugs Market size Outlook by Segments, 2021-2030
By Therapy
First line treatment
Second-line treatment
By Route of Administration
Oral
Parenteral
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
9 Meters Biopharma Inc
Almirall SA
Amgen Inc
AMYRA Biotech AG
Artielle Immunotherapeutics Inc
Avaxia Biologics Inc
BioLineRx Ltd
Bristol Myers Squibb Co.
Calypso Biotech BV
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
ImmunogenX Inc
Johnson and Johnson
Precigen Inc
Sanofi
Takeda Pharmaceutical Co. Ltd
Teva Pharmaceutical Industries Ltd
Vactech Oy
Zedira GmbH
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Therapy
First line treatment
Second-line treatment
By Route of Administration
Oral
Parenteral
The global Celiac Diseases Drugs Market is one of the lucrative growth markets, poised to register a 16.2% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
9 Meters Biopharma Inc, Almirall SA, Amgen Inc, AMYRA Biotech AG, Artielle Immunotherapeutics Inc, Avaxia Biologics Inc, BioLineRx Ltd, Bristol Myers Squibb Co., Calypso Biotech BV, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, ImmunogenX Inc, Johnson and Johnson, Precigen Inc, Sanofi, Takeda Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, Vactech Oy, Zedira GmbH
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume